Merck & Co., Inc. Sees Unusually High Options Volume (NYSE:MRK)

Key Points

• Merck saw unusual options activity on Wednesday, with investors buying 42,821 call options — about 42% above the stock’s typical daily call volume.
• The stock was trading up to $128.11, near its 52-week high of $131.74, while institutional ownership remained very high at 76.07%.
• Analysts remain broadly constructive on Merck, with an average Moderate Buy rating and a consensus price target of $133.94, even as the company’s dividend payout ratio is elevated at 95.77%.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) saw some unusual options trading activity on Wednesday. Stock investors acquired 42,821 call options on the stock. This is an increase of 42% compared to the typical daily volume of 30,188 call options.

Hedge Funds Weigh In On Merck & Co., Inc.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in Merck & Co., Inc. by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company's stock worth $26,770,014,000 after buying an additional 2,185,853 shares in the last quarter. State Street Corp raised its position in shares of Merck & Co., Inc. by 1.6% in the 4th quarter. State Street Corp now owns 120,040,168 shares of the company's stock valued at $12,737,504,000 after buying an additional 1,859,990 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Merck & Co., Inc. by 14.8% during the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Merck & Co., Inc. by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company's stock worth $6,307,572,000 after acquiring an additional 249,110 shares during the period. Finally, Morgan Stanley boosted its position in shares of Merck & Co., Inc. by 0.8% during the 4th quarter. Morgan Stanley now owns 44,946,021 shares of the company's stock worth $4,731,018,000 after acquiring an additional 359,486 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

NYSE:MRK traded up $1.85 during mid-day trading on Wednesday, reaching $128.11. 3,053,698 shares of the company's stock were exchanged, compared to its average volume of 10,928,491. Merck & Co., Inc. has a one year low of $76.66 and a one year high of $131.74. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The business's fifty day simple moving average is $120.65 and its two-hundred day simple moving average is $117.29. The firm has a market capitalization of $316.42 billion, a PE ratio of 36.04, a price-to-earnings-growth ratio of 4.95 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the previous year, the firm posted $2.22 EPS. The business's revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts anticipate that Merck & Co., Inc. will post 2.74 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were given a dividend of $0.85 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. Merck & Co., Inc.'s dividend payout ratio is currently 95.77%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Royal Bank Of Canada restated an "outperform" rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. BMO Capital Markets raised their price objective on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an "outperform" rating in a research report on Monday, July 13th. Guggenheim upped their target price on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a "buy" rating in a research report on Monday, July 13th. Citigroup started coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a "neutral" rating and a $125.00 target price on the stock. Finally, Weiss Ratings cut Merck & Co., Inc. from a "hold (c+)" rating to a "hold (c)" rating in a report on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $133.94.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.